1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

13.21
USD
-0.02
(-0.15%)
0.42EPS
33.96P/E
11.81BMarket Cap
Jan 22Next Earn
Dr. Reddy's Laboratories Ltd.
NYSE:RDY
(New York Stock Exchange)

Recent

price

13.21

P/E

ratio

33.96

div

yld

0.65%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
90.24
116.66
140.03
158.87
177.84
185.42
173.72
175.11
189.61
215.36
233.93
264.27
302.8
343.05
399.57
412.58
403.92
Revenue per Share
13.34
17.2
20.21
25.86
26.62
23.99
14.85
12.09
23.16
24.05
21.25
29.05
55.5
68.43
69.4
52.63
40.39
Basic EPS, GAAP
-4.35
9.12
7.2
10.62
11.65
31.61
-24.02
8.61
25.05
29.26
28.53
11.17
49.27
22.12
14.77
22.51
11.24
Free Cash Flow per Basic Share
3.7
2.67
3.27
3.59
4.3
4.92
4.18
4.92
4.93
4.83
5.11
5.11
6.13
8.17
8.18
8.18
8.12
Dividend per Share
55.56
69.27
87.63
109.14
133.57
153.81
153.03
155.85
172.85
191.17
213.53
234.75
284.26
344.48
409.67
462.96
470.6
Book Value per Share
37.14
52.96
70.75
91.48
113.86
124.28
92.98
95.95
113.34
152.13
163.91
195.73
241.07
293.88
276.21
318.13
327.66
Tangible Book Value per Share
828
829
830
832
833
834
811
811
811
811
811
811
812
814
815
814
820
Basic Weighted Avg Shares
74,693
96,737
116,266
132,170
148,189
154,708
140,809
142,028
153,851
174,600
189,722
214,391
245,879
279,164
325,535
335,933
331,186
Sales/Revenue/Turnover
16.45
18.88
18.04
19.66
17.84
19.22
9.64
8.47
12.89
18.77
17.35
16.75
24.02
23.39
22.12
14.92
10.89
Operating Margin (%)
4,148
5,213
5,549
7,106
8,100
10,250
11,277
11,710
12,190
12,472
12,796
11,824
12,636
14,841
17,058
20,605
21,212
Depreciation Expense
11,040
14,262
16,777
21,515
22,179
20,013
12,039
9,806
18,795
19,498
17,238
23,568
45,067
55,684
56,544
42,850
33,114
Net Income, GAAP
11.28
22.77
22.61
19.15
21.25
26.26
17.84
31.62
16.25
- -
34.74
27.03
25.34
22.52
25.45
22.53
20.77
Effective Tax Rate (%)
14.78
14.74
14.43
16.28
14.97
12.94
8.55
6.9
12.22
11.17
9.09
10.99
18.33
19.95
17.37
12.76
10
Profit Margin (%)
6,578
26,492
31,623
49,684
55,843
55,042
15,375
39,953
54,801
57,556
64,858
87,841
118,408
152,010
119,720
134,409
141,990
Working Capital
5,271
16,335
12,625
20,740
14,307
10,685
5,449
25,089
22,000
1,304
6,299
5,746
1,278
5,990
7,864
12,203
11,884
LT Debt
45,990
57,444
72,805
90,801
111,302
128,336
124,044
126,460
140,197
154,988
173,062
190,527
230,991
280,550
337,166
380,457
386,735
Total Equity
17.37
17.6
16.35
17.11
14.16
13.65
6.57
4.64
9.85
- -
8.34
10.04
18.15
19.19
15.59
9.26
6.06
Return on Invested Capital (%)
17.68
18.95
17.63
18.4
15.89
13.04
7.5
5.9
10.98
- -
9.39
11.35
19.68
20.92
16.93
10.96
8.55
Return on Capital (%)
24.84
27.58
25.77
26.3
21.95
16.7
9.54
7.83
14.1
13.21
10.51
12.96
21.38
21.77
18.42
12.06
9.03
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
56,124
65,138
60,068
LT Borrowings
- -
12,203
- -
LT Finance Leases
11,608
12,203
11,884
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
814
814
815
Market Capitalization
1,027,091
1,054,007
1,117,420

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
297,549
301,975
299,331
Cash, Cash Equivalents & STI
82,589
87,814
81,427
Accounts Receivable, Net
103,206
101,219
100,557
Inventories
79,009
76,531
80,473
Total Current Liabilities
158,310
167,566
157,341
Payables & Accruals
84,552
77,160
78,406
ST Debt
56,124
65,138
60,068
Deferred Revenue
1,780
1,581
1,744

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.75%
17.16%
12.84%
Free Cash Flow
14.05%
49%
52.37%
Net Income, GAAP
15.43%
25.76%
-24.22%
Sales/Revenue/Turnover
8.34%
12.21%
3.19%
Total Cash Common Dividend
5.81%
10.75%
-0.05%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
76,727
80,162
83,586
85,060
325,535
2026
85,452
88,051
87,268
75,162
335,933
2027
80,705
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
17.09
15.41
17.34
19.55
69.4
2026
17.42
17.22
14.86
2.71
52.63
2027
5.44
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
8.18
- -
- -
8.18
2026
- -
7.98
- -
- -
8.18
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Divi's Laboratories Limited (NSE:DIVISLAB)
Merck & Company, Inc. (NYSE:MRK)
Business
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company that develops, manufactures and markets generics, active pharmaceutical ingredients, biosimilars, branded generics and over-the-counter products worldwide; it offers finished dosage formulations including tablets, capsules, injectables and topical creams across therapeutic areas such as gastroenterology, cardiovascular, oncology, pain management, anti-infectives, diabetology, dermatology and pediatrics. Founded in 1984 by Kallam Anji Reddy and headquartered in Hyderabad, India, with U.S. headquarters in East Brunswick, New Jersey, the company operates manufacturing facilities in India, the UK and other regions, serving markets in North America, Europe, India, Russia and emerging economies. Its portfolio includes key active pharmaceutical ingredients like Abiraterone Acetate, Canagliflozin, Ciprofloxacin Hydrochloride, Ramipril and Ibuprofen; over 190 medications; diagnostic kits; and biotechnology products, supported by pharmaceutical services for custom development and contract manufacturing. Recent developments include a June 2025 collaboration with Alvotech to co-develop, manufacture and commercialize a pembrolizumab (Keytruda) biosimilar for global markets; acquisition of Haleon's global Nicotinell nicotine replacement therapy business (excluding the U.S.) for over Rs 5,000 crore; acquisition of U.S.-based MenoLabs to enter women's nutritional wellness; purchase of Novartis's Cidmus cardiovascular brand in India for Rs 456 crore; INR 700 crore investment in biosimilars and API capacity expansion, elevating annual capex to INR 1,400 crore; plans to launch generic weight-loss drugs in 87 countries including Canada, India and Brazil; and introduction of products like Toripalimab for nasopharyngeal carcinoma, a bevacizumab biosimilar in the UK, and Lenacapavir for HIV in partnership with Gilead Sciences.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

  • marketbeat.com

    Dr. Reddy's Laboratories Q2 Earnings Call Highlights

  • defenseworld.net

    Dr. Reddy’s Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • reuters.com

    India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • businesswire.com

    Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • gurufocus.com

    Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • gurufocus.com

    Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • businesswire.com

    Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • businesswire.com

    Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • gurufocus.com

    RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations